Trials / Recruiting
RecruitingNCT07135102
A Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of [225Ac]Ac-PSMA-XT Injection in Patients With Metastatic Castration-resistant Prostate Cancer
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Xiaorong Sun · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety and efficacy of 225Ac -labeled PSMA ligand(PSMA-XT) in the treatment of mCRPC
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 225Ac-PSMA-XT | Patients will receive 225Ac-PSMA-XT administration at an interval of 6 weeks between each dose. |
Timeline
- Start date
- 2024-10-14
- Primary completion
- 2026-12-31
- Completion
- 2027-06-01
- First posted
- 2025-08-21
- Last updated
- 2025-08-24
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07135102. Inclusion in this directory is not an endorsement.